Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2020 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.86%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 2.86%. Investors may view the EPS beat as a sign of improved operational efficiency. However, the lack of revenue data and forward guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.52	N/A	+19.45%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their operational progress. They highlighted the importance of their pipeline while acknowledging the challenges ahead.

Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.

They emphasized ongoing efforts in research and development.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.86%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.86%

Key numbers

Management commentary